Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.91
+0.27502.02%
Volume:136.75K
Turnover:1.88M
Market Cap:768.17M
PE:-5.04
High:13.94
Open:13.65
Low:13.55
Close:13.63
52wk High:16.93
52wk Low:6.47
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.62
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.88
PE(LYR):-5.75

Loading ...

Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral

MT Newswires Live
·
Sep 14

4D Molecular Therapeutics Price Target Announced at $20.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 14

4D Molecular Therapeutics Grants 96,000 Inducement RSUs to Seven New Employees

Reuters
·
Sep 12

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of 584 Common Shares for $8,176

Reuters
·
Sep 04

4D Molecular Therapeutics to Present at Wells Fargo, Cantor, Morgan Stanley Healthcare Investor Conferences

Reuters
·
Aug 25

4D Molecular Therapeutics CEO David Kirn Disposes of Common Shares Worth $1,068,651.63

Reuters
·
Aug 22

4D Molecular Therapeutics Posts Corporate Presentation Highlighting AAV Gene Therapy Pipeline Led by 4D-150 for Wet AMD, DME

Reuters
·
Aug 21

4D Molecular Therapeutics CLO Scott Bizily Disposes of Common Shares Worth $39,567.5

Reuters
·
Aug 18

B. Riley views EyePoint study miss as positive for 4D Molecular

TIPRANKS
·
Aug 18

4D Molecular Therapeutics Grants 35,200 RSUs to Five New Hires Under Inducement Award Plan

Reuters
·
Aug 15

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)

TIPRANKS
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Cantor Fitzgerald Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Analyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials

TIPRANKS
·
Aug 14

4D Molecular Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 Net Loss Widens

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 EPS $(1.04) Beats $(1.06) Estimate, Sales $3.781M Beat $3.100M Estimate

Benzinga Earnings
·
Aug 14

4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million

Reuters
·
Aug 14

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire
·
Aug 14

4D Molecular Therapeutics Inc Expected to Post a Loss of $1.02 a Share - Earnings Preview

Reuters
·
Aug 07